Immune–vascular mural cell interactions: consequences for immune cell trafficking, cerebral blood flow, and the blood–brain barrier

Anna Barkaway,* David Attwell*, and Nils Korte*
University College London, Department of Neuroscience, Physiology and Pharmacology, London, United Kingdom

Abstract. Brain barriers are crucial sites for cerebral energy supply, waste removal, immune cell migration, and solute exchange, all of which maintain an appropriate environment for neuronal activity. At the capillary level, where the largest area of brain–vascular interface occurs, pericytes adjust cerebral blood flow (CBF) by regulating capillary diameter and maintain the blood–brain barrier (BBB) by suppressing endothelial cell (EC) transcytosis and inducing tight junction expression between ECs. Pericytes also limit the infiltration of circulating leukocytes into the brain where resident microglia confine brain injury and provide the first line of defence against invading pathogens. Brain “waste” is cleared across the BBB into the blood, phagocytosed by microglia and astrocytes, or removed by the flow of cerebrospinal fluid (CSF) through perivascular routes—a process driven by respiratory motion and the pulsation of the heart, arteriolar smooth muscle, and possibly pericytes. “Dirty” CSF exits the brain and is probably drained around olfactory nerve rootlets and via the dural meningeal lymphatic vessels and possibly the skull bone marrow. The brain is widely regarded as an immune-privileged organ because it is accessible to few antigen-primed leukocytes. Leukocytes enter the brain via the meninges, the BBB, and the blood-CSF barrier. Advances in genetic and imaging tools have revealed that neurological diseases significantly alter immune–brain barrier interactions in at least three ways: (1) the brain’s immune-privileged status is compromised when pericytes are lost or lymphatic vessels are dysregulated; (2) immune cells release vasoactive molecules to regulate CBF, modulate arteriole stiffness, and can plug and eliminate capillaries which impairs CBF and possibly waste clearance; and (3) immune–vascular interactions can make the BBB leaky via multiple mechanisms, thus aggravating the influx of undesirable substances and cells. Here, we review developments in these three areas and briefly discuss potential therapeutic avenues for restoring brain barrier functions. © The Authors. Published by SPIE under a Creative Commons Attribution 4.0 International License. Distribution or reproduction of this work in whole or in part requires full attribution of the original publication, including its DOI. [DOI: 10.1117/1.NPh.9.3.031914]

Keywords: immune–vascular interactions; pericytes; leukocytes; cerebral blood flow; blood–brain barrier; waste clearance.

Paper 21070SSRR received Nov. 29, 2021; accepted for publication Apr. 13, 2022; published online May 14, 2022.

1 Introduction

Brain bordering tissues comprise the glia limitans, blood–brain and blood-cerebrospinal fluid (CSF) barriers, meninges, and skull bone marrow. They allow communication between the brain and peripheral immune system, facilitate cerebral supply of oxygen, glucose, ions, and various regulatory molecules while promoting the efflux of metabolic waste and limiting the influx of neurotoxic molecules, pathogens, and leukocytes. Over the past 15 years, the proposed existence of the glymphatic system, (re)discovery of the meningeal lymphatics, and advances in our understanding of cerebral immunosurveillance, the blood–brain barrier (BBB), and blood supply have given important new insight into how the brain functions. The brain exhibits

*Address all correspondence to Anna Barkaway, a.barkaway@ucl.ac.uk; David Attwell, d.attwell@ucl.ac.uk; Nils Korte; nils.korte.16@ucl.ac.uk
an immune-specialized status to minimize damage to its largely non-proliferating (and hence long-lived) cells, and therefore, leukocyte–vascular interactions and trafficking are tightly controlled. Neuroinflammation and microvascular dysfunction are hallmarks of various neurological diseases including, but not limited to, Alzheimer’s disease (AD), stroke, brain tumors, epilepsy, and multiple sclerosis (MS). Capillaries are the site of the greatest vascular resistance within the brain and provide the largest surface area for solute exchange. Control of capillary function is therefore crucial for regulating energy supply, BBB maintenance, and immune trafficking.

Following an overview of the brain vascular network and CSF transport routes, we will review recent advances in immune cell trafficking, immune modulation of cerebral blood flow (CBF), and BBB properties in various neurological diseases.

2 Overview of the Brain Vasculature and CSF Transport Routes

Blood enters the cerebral cortex from its surface through penetrating arterioles (PAs), goes through a vast network of capillaries for brain–blood and blood–brain solute exchange, and exits via ascending venules (AVs) (Fig. 1).

CBF is controlled by smooth muscle cells (SMCs) around arteries and arterioles and by pericytes with contractile processes wrapping circumferentially around capillaries. Advances in tools to optogenetically depolarize and transgenically label pericytes, to image their vasomotor tone and intracellular Ca\(^{2+}\) (\([\text{Ca}^{2+}]_i\)) activity in vivo, have revealed that pericytes throughout the capillary bed are contractile and that those of at least the first to third capillary branching order from PAs (where first-order refers to the first branch) contribute to neuronal activity evoked increases in CBF (Fig. 1). Pericytes are endowed with a wide range of ion channels allowing them to sense metabolic stimuli from the blood and brain to control CBF and solute transport appropriately (see Refs. 14–16 for transcriptome databases and Ref. 17 for a detailed review).

Respiratory motion, ciliary beating, vessel pulsation driven by the heart and spontaneous vasomotion of SMCs, and possibly pericytes of the first to third capillary branching order drive the flow of CSF, which facilitates brain buoyancy, waste clearance, and brain antigen presentation to systemic immune cells. CSF is generated by choroid plexus epithelial cells in the cerebral ventricles and circulates in the subarachnoid space from where it can enter the para-arterial spaces of PAs (Fig. 1). Pulses or spontaneous vasomotion move CSF either in a “reverse” manner back up the para-arterial spaces of PAs or through the brain via the postulated “glymphatic” system (involving water flow through the vascular endfeet of astrocytes), which drains cerebral interstitial fluid (ISF) possibly along AVs. This allows CSF to collect waste products and soluble antigens from the brain.

3 Immune Surveillance and Trafficking in the Brain: Pericytes as Immune Gatekeepers

3.1 Immune Surveillance

The brain is surveyed by microglia and astrocytes in the parenchyma, macrophages (MΦ) in the perivascular space, and by peripheral immune cells capturing brain antigens in the CSF and blood (Table 1).

Microglia are highly ramified cells that constantly survey the brain parenchyma for infection or injury, phagocytose dead neurons, monitor and prune synapses, and regulate neuronal activity, in part by forming purinergic somatic junctions with neurons and also by releasing adenosine onto neuronal A\(_1\) receptors. By extending and retracting their highly motile processes, microglia screen the entire brain parenchyma every few hours. A second mode of process motility called “chemotaxis” occurs when microglia send out processes toward sites of brain injury to confine brain damage, phagocytose cell debris, and limit secondary brain injury. Clearance of waste products is facilitated by tunnelling nanotubes connecting neighbouring microglia. Moreover, astrocytes, which are also capable of phagocytosis, occupy distinct phagocytic territories from those of microglia to aid in debris removal. Microglial
immunophenotypic features can vary considerably across brain regions, highlighting their heterogeneous nature. Microglia also closely associate with capillaries to modulate their functions (Fig. 2), as discussed in detail below.

It is now evident that brain immune surveillance is not restricted to microglia, but also involves brain border-associated immune cells that have phenotypic properties distinct from microglia as revealed by recent high dimensional single-cell cytometry studies. Border-associated immune cells screen CSF-derived molecules in the perivascular spaces, meninges (dura, arachnoid, and pia), choroid plexus, deep cervical lymph nodes, and possibly the...
### Table 1  Types of immune cell discussed in this review.

#### Peripheral immune cells

| Cell type     | Location                  | % of blood leukocytes | Numbers in blood (10³/µl) | Main immunological role                                                                                                                                                                                                 |
|---------------|---------------------------|-----------------------|---------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Neutrophil    | Peripheral blood          | 16* (mice) 60** (human) | 1.4* (mice) 3.4** (human) | Recruited to sites of infection/injury to kill via phagocytosis, release of granular contents or via pathogen trapping in extracellular traps; usually the first peripheral cells recruited to inflamed tissues.                                    |
| Monocyte      | Peripheral blood          | 5* (mice) 5** (human)  | 0.4* (mice) 0.26** (human) | Patrolling phagocytic cells involved in clearance of debris, phagocytosis, capturing and killing microbes once recruited to tissues.                                                                                          |
| B lymphocyte  | Peripheral blood          | 77* (mice)            | Total lymphocyte count 6.87* (mice) | Differentiate into plasma cells or memory B cells upon antigen recognition to produce antigen-specific antibodies for long-lasting immunity against secondary antigen challenges.                                      |
| CD4+ T lymphocyte | Peripheral blood and CSF | 27** (human)   | 1.52** (human)          | Recognize major histocompatibility complex (MHC) class II on APCs and aid recruitment of other immune cell subsets.                                                                                                       |
| CD8+ T lymphocyte | Peripheral blood and CSF |                        |                          | Recognize MHC class I and kill via secretion of cytokines, cytotoxic granules or by inducing apoptosis.                                                                                                               |

#### Major tissue immune cell types

| Cell type | Location                  | % of CNS leukocytes | Physiological role                                                                                                                                                                                                 |
|-----------|---------------------------|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PVM       | Perivascular space, meninges, and choroid plexus | ~10***                | Myeloid cells closely associated with the vasculature which scan the perivascular space, phagocytose debris and initiate recruitment of peripheral leukocytes.                                                        |
| Microglia | Brain parenchyma          | ~80***               | Resident immune cells of the brain that patrol the parenchyma, send out processes toward sites of injury to confine damage; scavenge foreign material, debris and synapses for removal; involved in synaptic pruning, neurogenesis and axonal growth. |
| DC        | Meninges and choroid plexus | ~3***                 | Role in antigen capture, processing and presentation to T cells to propagate immune responses.                                                                                                                        |
| Mast cell | Meninges, choroid plexus, and parenchyma | ~0.5***                | Derived from haematopoietic stem cells, long lived and resident cells, where they can interact with glia cells to orchestrate inflammation. Role not fully determined.                                                              |

---

*8–10 week old male mice.28  
**Male adults.29  
***2 month old C57BL6 mice as assessed by mass cytometry.30
skull. CSF antigens drained from the brain can enter the dura, where antigen-presenting cells (APCs) [including dendritic cells (DCs), MΦ, and B cells] capture brain antigens and present them to patrolling T cells (Fig. 3). In the dura, endothelial and mural cells (mainly pericytes and SMCs) recruit T cells by secreting the chemokine CXCL12, which binds to CXCR4 on T cells to promote their migration from the blood through the fenestrated endothelium of the dural venous sinuses. T cells modulate neuronal function probably by secreting cytokines from the meninges, or by migrating from the meninges into the brain, for instance, to program microglia to prune synapses or regulate neural stem cell proliferation. CSF in the dura can also drain through skull channels into the overlying bone marrow, which generates a rich pool of leukocytes that populates the meninges. Moreover, leukocytes may survey the brain in the CSF following their entry from the blood via the choroid plexus and possibly their

Fig. 2 Microglia–vascular interactions in the murine cerebral cortex—confocal images from murine brain slices depicting the cortical parenchymal vascular bed. Microglia (green: labeled for Iba1) are often closely associated with the vasculature (magenta: pericytes visualized using NG2-DsRed transgenic mice) and have processes that can directly contact the abluminal vessel wall.

Fig. 3 Dural immune cells survey brain antigens supplied by the draining CSF. CSF antigens may enter the dura through arachnoid granulations and become captured by APCs including DCs, MΦ, and possibly B cells. Endothelial (EC) or mural cell release of CXCL12 recruits T cells across the fenestrated endothelium of dural venous sinuses (on left), allowing T cells to survey antigens presented by APCs. CSF antigens are presented to immune cells in cervical lymph nodes (not shown) by being drained along perineural and dural lymphatic routes. Meningeal immune cells are repopulated by immune cells generated in the skull bone marrow. Figure created using BioRender.
movement along the perivascular space. The architecture of the vasculature, its cellular composition, and its perivascular spaces are diverse across the brain and its bordering tissues, leading to differences in the accessibility to and function of its associated immune cells [for detailed reviews on central nervous system (CNS) tissue immune cell differences see Refs. 68 and 69].

In the past, CSF was assumed to leave the brain either across the cribiform plate along (perineural) olfactory nerve rootlets into lymph vessels or by entering the blood via arachnoid villi and granulations somehow connecting to venous sinuses. Recent studies, however, suggest instead that CSF is also drained into the dura (possibly via arachnoid granulations) from where CSF enters the meningeal lymphatics, which project to deep cervical lymph nodes (Fig. 3). However, to date, the mechanism by which CSF crosses the arachnoid barrier into the venous sinus or dural lymphatics remains unknown. In fact, tight junctions between epithelial-like cells comprising the arachnoid should hinder the efflux of CSF and its constituents. Arachnoid granulations have thus been proposed to feature specialized structures for efflux, such as one-way valves or vacuole-forming channels. Furthermore, the relative contributions of olfactory perineural, venous sinus, and dural lymphatic routes to CSF efflux are unclear and a topic of ongoing discussion.

Peripheral blood leukocytes (Table 1) can also enter the brain across the BBB. Migration occurs across post-capillary vascular segments that connect to AVs. This is a two-step process: passage (1) across the vascular wall into the perivascular space, and subsequently (2) across the glia limitans that comprises the border between the perivascular space and the brain parenchyma. In the absence of neuroinflammation, leukocyte migration across the BBB is rare, and restricted to activated T cells, which cross the vasculature in an antigen non-specific manner. T cells need to recognize their cognate antigen from APCs in the perivascular space for them to cross the glia limitans. Pericytes may also be able to internalize and present antigens to T cells, in addition to stimulating the expansion of and cytokine secretion from T cells already primed by APCs. During neuroinflammation, however, neutrophils, monocytes, and B cells are also recruited across the BBB into the parenchyma (see Fig. 4). Erythrocytes are also key components of both immunosurveillance and the inflammatory response, by scavenging and sequestering mitochondrial deoxyribonucleic acid (DNA) via toll-like receptor 9 (TLR-9). During inflammation, the binding of DNA from bacteria, plasmodia, and mitochondria to erythrocyte TLR-9 increases neutrophil infiltration into the spleen, enhances interferon signaling and promotes anaemia by erythropagocytosis. Erythrocytes additionally scavenge chemokines, thus regulating chemokine concentrations in the plasma.

### 3.2 Pericyte Control of Leukocyte Trafficking

Recruitment of leukocytes into the brain is a key hallmark of numerous CNS disorders. For example, neutrophils enter the brain parenchyma early in the progression of AD. Following stroke, neutrophils may extravasate into the parenchyma or become trapped and confined within the neurovascular unit. In addition, the parenchymal infiltration of highly activated T and B cells is a probable driver of early MS pathology. Upregulation of adhesion molecules by ECs is considered a significant contributing factor to leukocyte influx in CNS disease and now a role for pericytes in leukocyte recruitment in the CNS is starting to emerge.

Since pericytes embedded in the basement membrane constitute the outermost layer of blood vessels, they are ideally situated to control multiple components of the immune response, as has been highlighted in the periphery. For example, during tumor necrosis factor (TNF) or interleukin (IL)-1β induced inflammation in the murine cremaster muscle, neutrophils are guided via pericyte intercellular adhesion molecule 1 (ICAM-1) to pericyte gaps to breach the vessel wall and enter the interstitium. In addition, in murine inflamed ear skin, pericytes on capillaries and arterioles aid chemotactic interstitial migration by interacting with neutrophils and monocytes via ICAM-1, and further support neutrophil migratory responses by providing chemokines, including macrophage migration inhibitory factor, C-C Motif Chemokine Ligand 2 (CCL2), and C-X-C Motif Chemokine Ligand 1 (CXCL1).

Intriguingly, while pericytes orchestrate and facilitate leukocyte entry in the periphery, in the CNS it was recently demonstrated that pericytes reduce the permissiveness of the vasculature to leukocyte entry. Mice lacking the PDGFβ receptor, Pdgfrα−/− (producing a
75% reduction in the number of pericytes in the brain) exhibit an intense influx of leukocytes in health and disease, presumably mediated by loss of pericyte-evoked suppression of ICAM-1 and vascular adhesion molecule 1 (VCAM-1) expression on ECs. This raises important questions regarding the function of pericytes during leukocyte recruitment in the brain: do brain pericytes prevent leukocyte entry unlike pericytes in other organs such as the cremaster muscle or ear skin, and mechanistically, how is this mediated? Do pericytes physically hinder leukocyte recruitment or do they produce factors involved in maintaining homeostasis to reduce immune cell entry, which may also impact the endothelial cell (EC) phenotype? This has been previously suggested by a study in the mouse retina, whereby depletion of pericytes induced a pro-inflammatory phenotype in ECs, characterized by increased expression of CCL2 or VCAM-1. In this context, one emerging mediator in
pericyte biology is IL-33, which is released via PDGFRβ signaling. IL-33 is considered to be an “alarmin” secreted by a wide range of stromal cells, which polarizes microglia toward an anti-inflammatory phenotype in mouse models of AD. As such, a lack of pericyte-derived IL-33 could further exacerbate immune cell recruitment and impact EC responses—aspects that remain to be investigated.

Furthermore, pericytes are involved in neuronal control of the CNS immune response, by sensing and relaying signals to neurons early in systemic inflammation. Following systemic lipopolysaccharide (LPS) stimulation in mice, PDGFRβ-expressing pericytes express high levels of the chemokine CCL2 during the initial acute phase of inflammation. Importantly, CCL2 acts on CCR2, the chemokine’s receptor on neurons, and enhances excitatory synaptic transmission. Given the early release of CCL2 from pericytes in this model, it will be important to define whether this is a transient response and if it is necessary for chronic inflammatory responses. Does pericyte-CCL2 work synergistically with, or independently from, CCL2 produced by microglia? Indeed, CCL2 is also a key factor that recruits monocytes and T cells to sites of inflammation, suggesting that pericyte-derived CCL2 may also act as a chemotactic molecule in this manner.

Chemokines are presented to leukocytes to facilitate migration into inflamed tissues—a process facilitated in part by the binding of tissue-derived chemokines on the abluminal side of ECs to atypical chemokine receptor 1 (ACKR1), a receptor that facilitates the internalization, transportation, and presentation of chemokines to leukocytes on the luminal aspect of ECs. For example, in the murine CNS, ACKR1 is upregulated in ECs during inflammation and shuttles chemokines across the BBB to be presented luminally, whereas erythrocyte ACKR1 acts as a chemokine reservoir. Other members of the ACKR family are involved in chemokine scavenge and degradation. To the best of our knowledge, no studies have investigated the expression and function of ACKRs on brain pericytes, despite RNAseq data suggesting brain pericytes could express some classes of ACKRs. Thus, pericytes may play a role in the retention, presentation, or degradation of chemokines via ACKRs, which is yet to be investigated.

In cancer, pericyte deficiency leads to increased leukocyte infiltration in murine experimentally induced tumors, IL-6 upregulation, and hypoxia. Importantly, the interaction of glioblastoma cells with human pericytes induces expression of anti-inflammatory cytokines IL-10 and TGF-β, which prevent attack of the tumor by host T cell mechanisms, hence promoting tumor survival. Furthermore, targeting glioma-derived pericytes can increase chemotherapeutic drug effusion into tumors. Hence, not only do pericytes provide a barrier to leukocyte entry in healthy conditions, but they can propagate tumor growth and malignancy by limiting tumor invasion by the host’s immune system. However, pericytes also play key roles in the vascularization of tumors via angiogenesis, therefore, suggesting a complicated role for pericytes in cancer.

In summary, it is now clear that pericytes are key mediators in the sensing and propagation of the inflammatory response. However, the role of pericytes seems to be highly organ-specific and dependent on the inflammatory stimulus. Crucially, detailed analysis of pericyte-leukocyte interactions in the CNS is required to understand whether mechanisms are shared between the CNS and the periphery.

4 Immune Cell Control of Blood Supply to the CNS

Over 100 years after their discovery, which highlighted their association with the vasculature (see Ref. for a historical overview), microglia are beginning to be recognized as an important modulator of microvascular blood flow in the healthy and diseased adult CNS. Peripheral immune cells and microglia generate peptides, purines, catecholamines, cytokines, chemokines, and reactive oxygen species (ROS) with established vasoactive properties. These soluble molecules modulate CBF, whether released locally from microglia or invading immune cells, from the perivascular space, or into the circulation from distal tissues such as the gut. Immune cells may also alter CBF by scavenging vasoconstrictors such as noradrenaline and endothelin-1 (as occurs in the periphery), degrading matrix proteins regulating vessel stiffness, contributing to the formation of capillary blocks, and eliminating capillaries by...
phagocytosis. Here, we review some of these emerging roles of immune cells in CBF control.

4.1 Microglia form Purinergic Junctions with Capillaries to Control CBF

Microglia can interact with capillaries by sensing purines released from pericytes, ECs or astrocyte endfeet on capillaries and, in pathology, by sensing entry of fibrinogen into the parenchyma from the blood. The purines, mainly adenosine triphosphate (ATP) and its hydrolysis product adenosine diphosphate (ADP), are sensed by microglial P2Y₁₂ receptors (P2Y₁₂Rs). Microglia are the only cells expressing P2Y₁₂Rs in the CNS parenchyma, although in the blood, ADP also activates P2Y₁₂Rs on platelets, enhancing their aggregation. Fibrinogen activates microglia by binding to the integrin receptor Mac1 (cluster of differentiation (CD)11b/CD18). P2Y₁₂R stimulation mediates /1 integrin activation in microglial processes required for chemotaxis toward sites of ATP/ADP released from capillaries, as occurs when brain injury releases ATP from damaged cells and raises [ATP]. Interestingly, microglial processes contact 83% of pericytes on capillaries, and cover 15% of the EC surface, predominantly at sites of mitochondria, which provide ATP released via capillary pannexin 1 (PANX1). High levels of P2Y₁₂Rs at the bulbous tips of microglial processes likely facilitate these contacts. Furthermore, 30% of all microglia somata are closely associated with capillaries. Microglia also contact capillary segments where astrocyte endfeet are absent, forming an integral part of the glia limitans, and so are ideally placed to modulate CBF.

Contradictory data exist on the role of microglia in CBF control. In P2Y₁₂R or PANX1 deficient mice, microglia-capillary interactions are reduced, and CBF is increased, suggesting that microglia confer vascular tone by a mechanism dependent on purinergic signaling. This is consistent with pharmacological microglial depletion increasing capillary diameter and CBF. Others, however, did not detect changes in CBF upon microglial depletion, possibly reflecting differences in anaesthetics used or brain regions imaged. Conceivably, CBF changes in P2Y₁₂R or PANX1 deficient mice may also be evoked by reductions in platelet aggregation in these mice. Furthermore, PANX1 modulates a wide range of physiological functions including inflammasome assembly, dendritic spine development, and sleep-wake cycle patterns, which may change CBF. Interestingly, global PANX1 KO in mice protects against cerebral infarction in ischaemia, and this is at least partially mediated by endothelial (but not mural cell) PANX1 KO reducing contractile tone and attenuating leukocyte infiltration. In contrast, P2Y₁₂R blockade increases infarct size and microglial elimination reduces CBF after experimental stroke in murine models. Microglial depletion, P2Y₁₂R knock-out, or pharmacological P2Y₁₂R blockade in mice also reduce neuronally evoked increases in CBF by ~16%, suggesting that microglia may contribute to neurovascular coupling (NVC). Importantly, P2Y₁₂R expression is reduced in various neurological diseases as shown in humans in AD and MS and in murine models of ischemic stroke, which may therefore alter microglia-capillary interactions and impair NVC in these diseases.

In summary, these studies suggest a role for microglia-mediated CBF control beyond that of vessel growth during development (Fig. 1) and warrant further research into the mechanisms by which PANX1 and P2Y₁₂Rs control CBF.

4.2 Immune Cells Signal to Mural Cells Directly via the Blood or CSF and Block Capillaries in Disease

Microglia and cerebral perivascular macrophages (PVMs) signal directly to mural cells to modulate CBF. This is facilitated by their close association with mural cells. Unlike microglia, however, PVMs lack ramified processes and P2Y₁₂Rs, and are located outside the glia limitans and within the perivascular space, closely juxtaposed to PAs and capillaries of at least the first to third branching order (Fig. 1). Peripheral immune cells also regulate mural cell contractile tone, although probably on a slower timescale, by releasing signaling molecules into the blood or CSF. Molecules released into the blood may act on ECs at the luminal side of the BBB, whereas those in the CSF may modulate vascular tone by entering the brain through the...
glia limitans at the pial surface or by being transported along perivascular and glymphatic routes (Figs. 1 and 3). Importantly, the glia limitans, arachnoid mater, and dural vasculature allow the passage of molecules up to \(~40\) kDa in size (e.g., 40-kDa dextran or HRP),\(^{25,169–171}\) which is larger than the size of most cytokines (\(~5\) to 25 kDa). Leukocytes in the meninges may therefore release molecules into the CSF to modulate CBF.

In the healthy murine brain, circulating leukocytes stall transiently in 0.4% of cerebral capillaries, possibly by interacting with the glycocalyx or selectins on ECs.\(^{128,172–174}\) However in disease, disruption of the glycocalyx, upregulation of selectins and adhesion molecules or any narrowing of the capillary lumen evoked by pericyte contraction or edema may cause leukocytes, which are less distensible and larger than erythrocytes, to become trapped in CNS capillaries. Neutrophil blocks were shown to occur in rodent models of stroke, diabetic retinopathy, sepsis, cerebral malaria, AD, and subcortical vascular dementia.\(^{128–131,175–180}\)

Similar vascular blocks by leukocytes can be observed in patients with AD\(^95\) and stroke,\(^99\) although the human leukocyte blood composition is remarkably different from that of mice (Table 1), in that there are more neutrophils and less lymphocytes (Table 1). In stroke patients, live computed tomography imaging of granulocytes labeled with a radioactive tracer revealed that granulocyte accumulation in regions of cerebral infarction correlates with worse neurological outcome and infarct volume.\(^{181,182}\) Since ischaemic stroke or the toxic build-up of Aβ oligomers in AD leads to pericytes constricting capillaries near their somata, where most circumferential processes are located,\(^5,8\) leukocytes may become trapped near pericyte somata as suggested by our data in a rodent model of stroke [Fig. 5(a)].\(^{183}\) Formation of capillary blocks may also be enhanced by neutrophils aggregating with platelets, possibly by generating extracellular DNA traps as occurs in arterial clots of ischemic stroke patients\(^{184,185}\) or by the release of inflammatory molecules as described below.

**Fig. 5** Mural cell leukocyte interactions modulating blood flow. (a) In vivo two-photon imaging of a neutrophil stalled near a pericyte soma in a cerebral capillary 1.5 h after bilateral common carotid artery occlusion in an adult mouse expressing dsRed under the pericyte NG2 promoter. Blood neutrophils are labeled using an antibody conjugated to Ly6G (0.1 mg/kg i.v.). Arrow indicates the narrowed lumen diameter at the pericyte soma. (b) Major ion channels and GPCRs modulating mural cell contractile tone in response to immune molecules. Stimulation of GPCRs coupled to \(G_\alpha\), \(G_{12/13}\), and \(G_i\) and \(Ca^{2+}\) influx through \(Ca_\text{v}\), promotes contraction, whereas GPCRs coupled to \(G_\alpha\), \(K^+\) efflux and GC activity reduce contraction. Immune cells may modulate contractility by releasing angiotensin II (Ang II), TNF-\(\alpha\), adenosine, PGE\(_2\), and NO. NO generated by nitric oxide synthase (NOS) activates mural cell GC, which promotes vasodilation by enhancing the activity of MLCP. NO levels are increased by IL-1\(\beta\) and reduced by IL-17 and IL-6 negatively regulating eNOS and by \(\bullet O_2\) reacting with NO. Figure created in part using BioRender.\(^{54}\)
4.3 Modes of Mural Cell Contraction by Immune Molecules

There are numerous immune-related molecules with known effects on blood flow. They include adenosine, angiotensin II (Ang II), prostaglandin E$_2$ (PGE$_2$), IL-1$\alpha$, and nitric oxide (NO) generated by microglia, histamine produced by mast cells, fractalkine (FKN) released by neurons, IL-17 generated by T helper cells, TGF-$\beta$ released from astrocytes, IL-10 released from T regulatory cells and ROS, IL-1$\alpha$, IL-1$\beta$, IL-6, and TNF$\alpha$ generated by various immune cells (Table 2).

There are established mechanisms by which these immune molecules may modulate the contractile tone of pericytes and SMCs [Fig. 5(b)]. Molecules may directly act on mural cells or signal through neighboring cells such as ECs to modulate the activity of mural cell ion channels, guanylyl cyclase (GC), or G-protein coupled receptors (GPCRs). GPCRs coupled to $G_{q/11}$, $G_s$, $G_{i/o}$, or $G_{12/13}$ $\alpha$ subunits can influence a wide range of $Ca^{2+}$-$s$, $Cl^-$-, $Na^+$-, or $K^+$-permeable surface membrane ion channels to regulate mural cell contractile tone. The surface membrane ion channels involved can be broadly divided into those having a hyperpolarizing or depolarizing influence on surface membrane potential ($V_m$). In addition there are $Ca^{2+}$-permeable channels in internal stores that are gated by inositol trisphosphate (IP$_3$) generated by $G_{q/11}$ activating phospholipase C.

Depolarization evokes $Ca^{2+}$ influx from the extracellular milieu via voltage-gated $Ca^{2+}$ channels ($Ca_{V}$).s. This [$Ca^{2+}$] rise causes $Ca^{2+}$ to bind to calmodulin (CaM). The $Ca^{2+}$-$CaM$ complex then activates myosin light chain kinase (MLCK), which in turn phosphorylates the myosin light chain (MLC) of myosin II causing actin-myosin crossbridge cycling and contraction [Fig. 5(b)]. In mural cells, $G_q$PCRs agonists activate MLCK by raising [$Ca^{2+}$]$_i$. Hyperpolarization, on the other hand, is primarily evoked by $K^+$ efflux, for instance, via inward rectifier $K^+$ (Kir2.1 and Kir2.2) or ATP-sensitive $K^+$ ($K_{ATP}$; Kir6.1) channels, causing voltage-gated calcium channels to close and vessels to dilate.

Signaling via GC or GPCRs coupled to $G_s$, $G_{i/o}$, or $G_{12/13}$ modulates the activity of myosin light chain phosphatase (MLCP), which dephosphorylates MLC to reduce contraction. While GC and GPCRs enhance MLCP activity by facilitating cAMP production via adenylate cyclase (AC), GPCRs and $G_{12/13}$PCRs have an opposing effect; they negatively regulate MLCP by inhibiting AC or stimulating rho-associated protein kinase, respectively, thus evoking contraction. $G_q$PCRs agonists such as adenosine can also hyperpolarize mural cells by evoking $K^+$ efflux via $K_{ATP}$ channels.

4.4 Microglia and Peripheral Immune Cells Release Vasoactive Molecules to Control Blood Flow

Microglia generate vasodilating adenosine by hydrolyzing ATP using the membrane-bound ectoenzymes CD39 and CD73. This may facilitate capillary dilation, at least in conditions of hypercapnic CO$_2$ challenge in mice, and it may also contribute to adenosine-evoked increases in CBF during NVC. Adenosine relaxes pericytes via $G_s$-coupled adenosine receptors [Fig. 5(b)]. In contrast, ATP and ADP contract pericytes by stimulating P2X receptors (P2X-gated channels mediating cation influx) and $G_q$-coupled P2Y$_1$ and P2Y$_2$ receptors (promoting $Ca^{2+}$ release from stores), respectively. ATP hydrolysis by microglia may thus attenuate contractile tone.

Microglia can also produce the prostanoid PGE$_2$ via cyclooxygenase (COX) and IL-1$\beta$ via the NLRP3 inflammasome. PGE$_2$ evokes capillary dilation by stimulating $G_s$-coupled EP$_4$ receptors on pericytes and $G_q$-coupled endothelial EP1 receptors, whereas IL-1$\beta$ activates its receptors predominantly on ECs, which increases CBF by promoting the release of NO. However, prolonged IL-1$\beta$ application was found to enhance hypoperfusion, likely by promoting inflammation and leukocyte infiltration.

Since microglial [$Ca^{2+}$]$_i$ transients are partly driven by the activity of neurons and regulate COX, and NLRP3 and matrix metalloproteinase (MMP)-mediated cleavage of membrane-bound cytokines into their soluble forms, it is conceivable that neurotransmitters modulate microglial-evoked changes in CBF. Indeed, the factors controlling the release of various vasoactive
| **Table 2** Possible pathways mediating immune cell regulation of vascular tone in health and disease. |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| **Expected vasomotor effect** | **Generating cell type** | **Agent** | **Mechanism** |
| Vasodilation or increased blood flow | Microglia | NO | Stimulates mural cell GC |
| | | PGE2 | GPCR-coupled adenylate receptors on mural cells |
| | | IL-1β | GqPCR-coupled EP4 receptors on pericytes and Gi-coupled endothelial EP1 receptors |
| | | ROS | ATP-gated and Ca2+-activated K+ channels in SMCs |
| | | IL-10 | Increases blood flow by stimulating NO release |
| | | FKN | Stimulates microglia to release Ang II acting on Ang II type 1 receptors on mural cells |
| | T regulatory cells | IL-10 | Reduces Ang II evoked release of O2- |
| | Various leukocytes | IL-17 | Negatively regulates eNOS by enhancing its Thr495 phosphorylation |
| Vasoconstriction or decreased blood flow | Microglia, perivascular MΦ, blood and meningeal leukocytes | ROS | Inflammation and leukocyte infiltration |
| | | Angiotensin II | Gq-coupled Ang II type 1 receptors on mural cells |
| | | | Ca2+ release from stores in pericytes; reduces NO bioavailability; stimulates release of endothelin-1 activating Gq-coupled ETA receptors on pericytes |
| | | | Stimulates microglia to release Ang II acting on Ang II type 1 receptors on mural cells |
| | | | Negatively regulates eNOS by enhancing its Thr495 phosphorylation |

References:
188,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,
prostanoids (via COX) and cytokines (via NLRP3 or MMPs) are largely unexplored in immune cells. Transcriptome studies, for instance, suggest that microglia are uniquely endowed with the enzyme thromboxane A2 synthase (downstream of COX) that generates the prostanoid thromboxane A2, which contracts pericytes, whereas the cytokine IL-1α is generated in microglia and evokes dilation of pial arteries.

Neurons also signal to microglia to alter blood flow via the chemokine fractalkine (FKN/CX3CL1). FKN is predominantly present in neurons (membrane-bound or released in a soluble form) and binds to CX3CR1 selectively expressed in microglia or MΦ. In the healthy brain, FKN promotes synaptic strength, neurogenesis, and memory formation and may act as a "find me" signal for microglia to clear neuronal debris, but, after stroke, signaling via FKN reduces CBF, enhances neuronal apoptosis and worsens neurological outcome in mice. In the mouse retina, application of soluble FKN (mimicking its release from damaged neurons) evokes rapid capillary constriction, possibly by a mechanism involving microglial release of Ang II acting on Gq and Gq-coupled Ang II type 1 receptors. Furthermore, our unpublished data show that FKN contracts pericytes and decreases blood flow in the murine cerebral cortex. Blocking CX3CR1 may thus provide a therapeutic approach to reduce the constriction of pericytes that contributes to the no-reflow of blood in capillaries after stroke.

ROS generated by NADPH oxidase (NOX2) in immune cells can be released in the brain by microglia, PVMs or infiltrating leukocytes in the blood by circulating leukocytes such as neutrophils (e.g., after stroke in humans) or from the meninges into the brain (e.g., after traumatic brain injury). ROS directly modulate the contractile tone of pericytes and SMCs; in pericytes by stimulating Ca2+ release from stores (possibly via endothelin-1 release), which raises [Ca2+], and enhances vasoconstriction and in SMCs by activating ATP-gated and Ca2+-activated K+ channels, which hyperpolarize Vm and evoke vasodilation. ROS release following ischemic stroke induces pericyte contraction and contributes to capillary no-reflow, which can be partially reversed with a NOX2 blocker.

Superoxide (•O2) generated by NOX2 can also react with endothelial-derived NO to form peroxynitrite, thus reducing NO bioavailability. Indeed, NO-mediated increases in CBF evoked by neuronal activity are impaired by PVMs producing •O2, for instance, in response to Ang II binding to AT1 receptors or activating the innate immunity receptor CD36. Aβ also evokes release of ROS from pericytes (via NOX4) and from microglia (via NOX2), causing pericyte contraction by a mechanism dependent on downstream release of endothelin-1 activating Gq-coupled ETA receptors. ROS and endothelin-1 are also thought to contribute to cerebral hypoperfusion in patients with MS. The anti-inflammatory cytokine IL-10 released by T regulatory cells largely prevents the Ang II evoked release of •O2 and restores NVC, which is consistent with the cerebroprotective function of IL-10 after stroke in mice.

In mice on a high salt diet, gut T helper (TH17) cell release of IL-17 into the circulation reduces the activity of eNOS, which reduces CBF by 25%. Elevated levels of IL-17 found in the blood of patients with AD, MS and stroke and infiltrating neutrophils releasing IL-17 in the cortex of AD mice may reduce endothelial NOS (eNOS) activity in a similar manner. Furthermore, elevated plasma levels of IL-6, which promotes coagulation and negatively regulates eNOS (by inhibiting its phosphorylation at Ser1177), were associated with CBF decreases in aging individuals, stroke patients, and in patients recovered from COVID-19.

Importantly, systemic infection evoked decreases in CBF may enhance cognitive decline in patients. For instance, 62% of hospitalized COVID-19 patients present with a reduction in brain energy supply, most commonly, in the form of an ischemic stroke and 34% show neurological and psychiatric deficits in the six months following COVID-19 infection. Cerebral ischemia evoked by capillary constriction is thought to be a major cause of brain injury in patients with sepsis, which occurs when the immune system excessively generates cytokines in response to infection. A similar "cytokine storm" occurs in severe COVID-19 patients, although, similar to human immunodeficiency virus (HIV), SARS-CoV-2 induces profound lymphopenia, in particular a reduction in CD4+ and CD8+ T cells. Notably, a decline in CD4+ T cells in HIV patients or in a macaque model of AIDS correlates with a decrease in CBF. Although respiratory failure is a major risk factor for cerebral ischemia in COVID-19 patients, SARS-CoV-2...
also impairs the cerebral vasculature directly by inducing pericyte contraction, and microthrombi formation. Systemic infection also exacerbates cerebral hypoperfusion in AD patients, presumably by inducing the release of cytokines, which is expected to accelerate cognitive decline in these patients. Interventions aimed at restoring CBF following severe infection may thus help to improve cognition in these patients.

5 Do Immune Cells Contribute Significantly to the Maintenance and Disruption of the Blood–Brain Barrier?

The BBB is a highly specialized vascular barrier that limits the influx of serum proteins, leukocytes, and toxic substances such as glutamate and ATP into the brain parenchyma and pumps out waste—functions that are primarily mediated by ECs, pericytes, and astrocytes (Fig. 4). The BBB results from: (1) transendothelial tight junctions between ECs that confer a high resistance to paracellular diffusion of solutes, (2) suppression of endocytic vesicle-mediated transcytosis of macromolecules such as proteins and peptides, and (3) solute carriers that transport carbohydrates, vitamins, amino acids, hormones, monocarboxylic acids, and nucleotides. CNS ECs exhibit a BBB-specific gene expression profile, with similar core changes in gene expression being observed across different CNS disorders. This specialized layer of ECs is held together by tight junctions (e.g., occludin and claudin, which link the cytoskeleton through scaffolding proteins such as zona occludens-1) and adherens junctions (cadherins, which connect intracellular actin filaments via α, β, and γ catenins). The BBB maintains low levels of permeability-enhancing proteins on ECs including the Tie2 ligand angiopoietin-2 and the plasmalemna vesicle-associated protein, which is required for endothelial vesicle trafficking. Expression of various leukocyte adhesion molecules (ICAM1, VCAM1, activated leukocyte cell adhesion molecule (ALCAM), and galectin-3) are also suppressed. This is to limit leukocyte influx, which can contribute to BBB leakiness caused by disruption of EC junctional molecules and the extracellular matrix via leukocyte release of (1) pro-inflammatory cytokines, such as TNF, (2) ROS, or (3) MMPs. These leukocyte-derived molecules are also able to induce neurotoxicity.

In the brain, ECs show a lower rate of transcytosis than ECs of any other organ. This is in part because the major facilitator superfamilly domain—containing 2a (Mfsd2a) protein, a sodium-dependent lysophosphatidylcholine transporter—suppresses transcytosis in capillaries (but notably not in arterioles) because lipids transported by Mfsd2a establish a unique lipid composition of CNS EC plasma membranes that inhibits endothelial caveolae vesicle formation. With age, Mfsd2a becomes downregulated, whereas caveolin vesicle density is increased, in association with reduced pericyte coverage and increased BBB permeability. In addition, the level of Mfsd2a is reduced upon LPS exposure, suggesting its expression can be modulated by inflammation. Interestingly, lymphocyte transcellular migration (migration through the EC body) relies on the translocation of ICAM-1 to caveolae-rich domains of ECs, to create a path through which the lymphocyte can migrate, and ECs, which exhibit low Mfsd2a levels have high ICAM-1 expression. Thus, the same factors regulating transcytosis of molecules may also influence transcellular migration of lymphocytes.

Key to the development and maintenance of the BBB are pericytes, which are essential for the development of tight junctions between ECs and the expression of Mfsd2a in ECs, thus suppressing permeability-enhancing proteins. The stabilization of tight junctions by secretion of angiopoietin-1 and inducing growth of the endothelial tube, which is suggested to widen capillary diameters near pericyte somata. Pericyte deficiency in mutant mice (with low levels of PDGFRβ or lacking the PDGF-BB retention motif) severely impairs the BBB. This results in an influx of toxic blood-borne solutes (e.g., cytokines and serum proteins), impaired function of ECM proteins, disrupted expression of leukocyte adhesion molecules, activation of microglia, and damage to neurons. Accordingly, in AD patients' brains, pericyte loss correlates with enhanced BBB leakage. Additionally, increased soluble PDGFRβ in the CSF correlates with increased measures of BBB dysfunction and cognitive impairment, highlighting the key importance of this cell type for maintaining a healthy BBB and avoiding pathology. Activation of the CypA-MMP9 pathway in pericytes (e.g., in ApoE4 carriers) can contribute to BBB breakdown, highlighting how crucial this cell type is for barrier function.
Ablation of microglia in the healthy murine CNS does not compromise BBB integrity. However, microglia do play a key role in the rapid repair of the vasculature upon BBB impairment. Specifically, in a manner dependent on ADP-sensing P2Y12 receptors, microglia extend processes toward, and aggregate at, sites of vascular damage (as induced by laser injury) and seal the broken vessel using a mechanism dependent on E-cadherin. In addition, microglia may also secrete trophic factors to encourage endothelial growth. This phenomenon has been further explored in zebrafish with respect to MΦ, where these cells physically repair vessels by pulling two endothelial ends together in a microfilament-dependent manner. Thus, immune cells can repair damage by providing adhesive molecules and by physical traction.

Recent data also suggest that microglia play dual roles in the regulation of the BBB, dependent on the timing of the inflammatory response. Initially, following LPS challenge in mice, microglial contact with cerebral blood vessels protects BBB integrity, by increasing expression of the tight junctional protein claudin-5, a phenomenon that has also been shown to be mediated by astrocytes. However, prolonged inflammation results in a more activated microglial phenotype, resulting in phagocytosis of astrocytic end-feet and BBB integrity loss. In mild hypoxia in the spinal cord, microglial depletion enhances tight junction loss and BBB permeability. In the brain following stroke in mice, microglia migrate toward the hypoxic vasculature and, in principle, aid repair by phagocytosing and clearing damaged sites. However, this leads to a positive feedback loop, where the vasculature becomes leaky to the blood serum components albumin and fibrinogen, which upregulates expression of inflammatory cytokines, and promotes further recruitment of microglia. Indeed, deposition of fibrinogen in the parenchyma as a consequence of BBB dysregulation in mouse models of MS induces vascular microglia clustering, contributing to neuronal damage. Therefore, while the primary role of microglia is protective, the consequences of their actions can be damaging to the parenchyma, as occurs following ischaemia and in AD patient brains. These studies highlight that the role microglia play, whether protective or destructive, is very much dependent on the type of injury, and the time frame.

While microglia play key roles in the regulation of the BBB, peripheral leukocytes predominantly contribute to BBB breakdown during pathology. These actions can be mediated by ROS and MMP release, which damage EC junctions, for example by interfering with the β-catenin complex. Neutrophils are rich sources of these mediators, and contribute to the breakdown of the BBB in various neurological pathologies, and T cells have also been shown to mediate damage in this manner. Infiltrating T cells can perturb the BBB via the action of cytokines IL-17 and IL-22, which release ROS from ECs, disrupting tight junctions. In addition, prolonged stalling of neutrophils in vessels may impair the integrity of the BBB by enhancing endothelial actin depolymerization and the breakdown of adherens junctions between ECs, as occurs in the periphery. More recently, neutrophil extracellular traps (NETs) have been observed to form both intravascularly and extravascularly during neurological disease, which may contribute to BBB permeability increases. NETs are structures formed by highly activated neutrophils that extrude DNA and intracellular contents to capture pathogens, degrade bacterial toxic factors, and kill bacteria. Neutrophils from mice subjected to stroke are more likely to form NETs, and removal of NETs reduces BBB leakage and improves pericyte coverage. The mechanism by which NETs induce BBB breakdown is not yet clear, but since NETs expose and spill intracellular content (histones, and granule content including proteases), it is likely that proteases and ROS contribute.

In summary, microglia can play protective and detrimental roles in the regulation of the BBB, but peripheral blood leukocytes are predominantly destructive in pathology.

6 Summary and Possible Therapeutic Avenues

Immune–vascular interactions are a therapeutic target for various neurological diseases. CBF decreases occurring after stroke or early in the progression of AD could, for instance, be therapeutically targeted by inhibiting FKN receptors or blocking ROS production, respectively. This may reduce the plugging of capillaries by blood leukocytes, improve energy supply, and reduce capillary pericyte and neuronal loss in later stages of...
Pericyte degeneration also occurs early in human MS, and pericyte-deficiency in an MS mouse model is lethal due to excessive immune cell influx. A possible therapeutic strategy may thus aim to restore pericyte coverage to improve barrier function in these diseases.

Another clinical approach could involve recruiting immune cell subsets with protective properties to the diseased brain. Promising murine studies highlight that recruitment of regulatory T cells improves cognitive function in AD, promotes microglia-mediated oligodendrogenesis following stroke, prevents Ang II evoked disruption of NVC and ameliorates neutrophil MMP-9 mediated BBB breakdown. Furthermore, augmenting immunosurveillance of the brain by enhancing lymphatic drainage (promoting antigen exposure to immune cells) facilitates the CD8+ T cell mediated clearance of brain tumors. A similar approach could be adopted to manipulate pericytes to allow drug and immune cell access specifically to tumors.

In conclusion, immune–vascular interactions play both homeostatic and pathogenic roles in the CNS depending on the context and injury. This field is currently at an exciting stage, where future work will identify new therapeutic avenues to help combat CNS disease.

Disclosures
No conflicts of interest, financial or otherwise, are declared by the authors.

Acknowledgments
This work is supported by the European Research Council (Grant No. 740427) and the Wellcome Trust (Grant No. 219366/19/Z).

References
1. I. G. Gould et al., “The capillary bed offers the largest hemodynamic resistance to the cortical blood supply,” J. Cereb. Blood Flow Metab. 37(1), 52–68 (2017).
2. A. Montagne, Z. Zhao, and B. V. Zlokovic, “Alzheimer’s disease: a matter of blood–brain barrier dysfunction?” J. Exp. Med. 214(11), 3151–3169 (2017).
3. A. Krogh, “Studies on the capillariometer mechanism: I. The reaction to stimuli and the innervation of the blood vessels in the tongue of the frog,” J. Physiol. 53(6), 399–419 (1920).
4. C. M. Peppiatt et al., “Bidirectional control of CNS capillary diameter by pericytes,” Nature 443(712), 700–704 (2006).
5. R. Nortley et al., “Amyloid beta oligomers constrict human capillaries in Alzheimer’s disease via signaling to pericytes,” Science 365(6450), eaav9518 (2019).
6. H. J. Knot and M. T. Nelson, “Regulation of arterial diameter and wall [Ca2+] in cerebral arteries of rat by membrane potential and intravascular pressure,” J. Physiol. 508(1), 199–209 (1998).
7. A. L. Gonzales et al., “Contractile pericytes determine the direction of blood flow at capillary junctions,” Proc. Natl. Acad. Sci. U. S. A. 117(43), 27022–27033 (2020).
8. C. N. Hall et al., “Capillary pericytes regulate cerebral blood flow in health and disease,” Nature 508(7494), 55–60 (2014).
9. K. Kisler et al., “Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease,” Nat. Rev. Neurosci. 18(7), 419–434 (2017).
10. D. A. Hartmann et al., “Brain capillary pericytes exert a substantial but slow influence on blood flow,” Nat. Neurosci. 24(5), 633–645 (2021).
11. A. Mishra et al., “Astrocytes mediate neurovascular signaling to capillary pericytes but not to arterioles,” Nat. Neurosci. 19(12), 1619–1627 (2016).
12. A. R. Nelson et al., “Channelrhodopsin excitation contracts brain pericytes and reduces blood flow in the aging mouse brain in vivo,” Front. Aging Neurosci. 12, 108 (2020).
13. R. L. Rungta et al., “Vascular compartmentalization of functional hyperemia from the synapse to the pia,” Neuron 99(2), 362–375e4 (2018).
14. M. Vanlandewijck et al., “A molecular atlas of cell types and zonation in the brain vasculature,” *Nature* 554(7693), 475–480 (2018).
15. A. C. Yang et al., “Physiological blood–brain transport is impaired with age by a shift in transcytosis,” *Nature* 583(7816), 425–430 (2020).
16. A. Zeisel et al., “Molecular architecture of the mouse nervous system,” *Cell* 174(4), 999–1014.e22 (2018).
17. A. Hariharan et al., “The ion channel and GPCR toolkit of brain capillary pericytes,” *Front. Cell Neurosci.* 14, 601324 (2020).
18. J. J. Iliff et al., “Cerebral arterial pulsation drives paravascular CSF-interstitial fluid exchange in the murine brain,” *J. Neurosci.* 33(46), 18190–18199 (2013).
19. H. Mestre et al., “Flow of cerebrospinal fluid is driven by arterial pulsations and is reduced in hypertension,” *Nat. Commun.* 9, 4878 (2018).
20. S. J. van Veluw et al., “Vasomotion as a driving force for paravascular clearance in the awake mouse brain,” *Neuron* 105(3), 549–561.e5 (2020).
21. J. N. Haidey et al., “Astrocytes regulate ultra-slow arteriole oscillations via stretch-mediated TRPV4-COX-1 feedback,” *Cell Rep.* 36(5), 109405 (2021).
22. W. C. Cole, G. R. Gordon, and A. P. Braun, “Cellular and ionic mechanisms of arterial vasomotion,” *Adv. Exp. Med. Biol.* 1124, 297–312 (2019).
23. E. W. Olstad et al., “Ciliary beating compartmentalizes cerebrospinal fluid flow in the brain and regulates ventricular development,” *Curr. Biol.* 29(2), 229–241.e6 (2019).
24. S. Dreha-Kulaczewski et al., “Inspiration is the major regulator of human CSF flow,” *J. Neurosci.* 35(6), 2485–2491 (2015).
25. J. J. Iliff et al., “A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta,” *Sci. Transl. Med.* 4(147), 147ra111 (2012).
26. A. K. Diem et al., “Arterial pulsations cannot drive intramural periarterial drainage: significance for abeta drainage,” *Front. Neurosci.* 11, 475 (2017).
27. D. Schley et al., “Mechanisms to explain the reverse perivascular transport of solutes out of the brain,” *J. Theor. Biol.* 238(4), 962–974 (2006).
28. Charles River Laboratories, “C57BL6 mouse model information sheet,” 2019, https://www.criver.com/sites/default/files/resources/C57BL6MouseModelInformationSheet.pdf.
29. S. Melzer et al., “Reference intervals for leukocyte subsets in adults: results from a population-based study using 10-color flow cytometry,” *Cytometry B Clin. Cytom.* 88(4), 270–281 (2015).
30. D. Mrdjen et al., “High-dimensional single-cell mapping of central nervous system immune cells reveals distinct myeloid subsets in health, aging, and disease,” *Immunity* 48(3), 599 (2018).
31. D. Davalos et al., “ATP mediates rapid microglial response to local brain injury in vivo,” *Nat. Neurosci.* 8(6), 752–758 (2005).
32. U. K. Hanisch and H. Kettenmann, “Microglia: active sensor and versatile effector cells in the normal and pathologic brain,” *Nat. Neurosci.* 10(11), 1387–1394 (2007).
33. A. Nimmerjahn, F. Kirchhoff, and F. Helmchen, “Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo,” *Science* 308(5726), 1314–1318 (2005).
34. S. Koizumi et al., “UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis,” *Nature* 446(7139), 1091–1095 (2007).
35. D. P. Schafer et al., “Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner,” *Neuron* 74(4), 691–705 (2012).
36. M. E. Tremblay, R. L. Lowery, and A. K. Majewska, “Microglial interactions with synapses are modulated by visual experience,” *PLoS Biol.* 8(11), e1000527 (2010).
37. H. Wake et al., “Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals,” *J. Neurosci.* 29(13), 3974–3980 (2009).
38. Y. Li et al., “Reciprocal regulation between resting microglial dynamics and neuronal activity in vivo,” *Dev. Cell.* 23(6), 1189–1202 (2012).
39. C. Cserep et al., “Microglia monitor and protect neuronal function through specialized somatic purinergic junctions,” *Science* 367(6477), 528–537 (2020).
40. A. Badimon et al., “Negative feedback control of neuronal activity by microglia,” *Nature* **586**(7829), 417–423 (2020).
41. C. Herzog et al., “Reactive astrocytes mediate synapse elimination through MEGF10 and MERTK pathways;” *Nature* **504**(7480), 394–400 (2013).
42. H. Scheiblich et al., “Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes,” *Cell* **184**(20), 5089–5106e21 (2021).
43. W. S. Chung et al., “Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways;” *Nature* **504**(7480), 394–400 (2013).
44. H. Van Hove et al., “Unexpected role of interferon-gamma in regulating neuronal connectivity and social behaviour,” *Nature* **590**(7847), 612–617 (2021).
45. Y. M. Morizawa et al., “Reactive astrocytes function as phagocytes after brain ischemia via ABCA1-mediated pathway,” *Nat. Commun.* **8**, 28 (2017).
46. J. H. Lee et al., “Astrocytes phagocytose adult hippocampal synapses for circuit homeostasis,” *Nature* **590**(7847), 612–617 (2021).
47. P. Prakash et al., “Monitoring phagocytic uptake of amyloid beta into glial cell lysosomes in real time,” *Chem. Sci.* **12**(32), 10901–10918 (2021).
48. E. C. Damisah et al., “Astrocytes and microglia play orchestrated roles and respect phagocytic territories during neuronal corpse removal in vivo,” *Sci. Adv.* **6**(26), eaba3239 (2020).
49. K. Grabert et al., “Microglial brain region-dependent diversity and selective regional sensitivities to aging,” *Nat. Neurosci.* **19**(3), 504–516 (2016).
50. H. Van Hove et al., “A single-cell atlas of mouse brain macrophages reveals unique transcriptional identities shaped by ontogeny and tissue environment,” *Nat. Neurosci.* **22**(6), 1021–1035 (2019).
51. S. P. das Neves, N. Delivanoglou, and S. Da Mesquita, “CNS-draining meningeal lymphatic vasculature: roles, conundrums and future challenges,” *Front. Pharmacol.* **12**, 655052 (2021).
52. Z. Papadopoulos, J. Herz, and J. Kipnis, “Meningeal lymphatics: from anatomy to central nervous system immune surveillance,” *J. Immunol.* **204**(2), 286–293 (2020).
53. T. Korn and A. Kallies, “T cell responses in the central nervous system,” *Nat. Rev. Immunol.* **17**(3), 179–194 (2017).
54. https://BioRender.com.
55. J. Rustenhoven et al., “Functional characterization of the dural sinuses as a neuroimmune interface,” *Cell* **184**(4), 1000–1016e27 (2021).
56. B. Engelhardt, P. Vajkoczy, and R. O. Weller, “The movers and shapers in immune privilege of the CNS,” *Nat. Immunol.* **18**(2), 123–131 (2017).
57. N. C. Derecki et al., “Regulation of learning and memory by meningeal immunity: a key role for IL-4,” *J. Exp. Med.* **207**(5), 1067–1080 (2010).
58. A. J. Filiano et al., “Unexpected role of interferon-gamma in regulating neuronal connectivity and social behaviour,” *Nature* **535**(7612), 425–429 (2016).
59. E. Pascuito et al., “Microglia require CD4 T cells to complete the fetal-to-adult transition,” *Cell* **182**(3), 625–640e24 (2020).
60. B. W. Dulken et al., “Single-cell analysis reveals T cell infiltration in old neurogenic niches,” *Nature* **571**(7764), 205–210 (2019).
61. S. Brioschi et al., “Heterogeneity of meningeal B cells reveals a lymphopoietic niche at the CNS borders,” *Science* **373**(6553), eaba9277 (2021).
62. R. Cai et al., “Panoptic imaging of transparent mice reveals whole-body neuronal projections and skull-meninges connections,” *Nat. Neurosci.* **22**(2), 317–327 (2019).
63. A. Cugurra et al., “Skull and vertebral bone marrow are myeloid cell reservoirs for the meninges and CNS parenchyma,” *Science* **373**(6553), eaba7844 (2021).
64. F. Herisson et al., “Direct vascular channels connect skull bone marrow and the brain surface enabling myeloid cell migration,” *Nat. Neurosci.* **21**(9), 1209–1217 (2018).
65. F. E. Pulou et al., “Cerebrospinal fluid outflow through skull channels instructs cranial hematopoiesis,” bioRxiv (2021).
66. H. Yao et al., “Leukaemia hijacks a neural mechanism to invade the central nervous system,” *Nature* **560**(7716), 55–60 (2018).
67. P. Kivisakk et al., “Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin,” Proc. Natl. Acad. Sci. U. S. A. 100(14), 8389–8394 (2003).

68. K. Kierdorf et al., “Macrophages at CNS interfaces: ontogeny and function in health and disease,” Nat. Rev. Neurosci. 20(9), 547–562 (2019).

69. D. A. D. Munro, K. Movahedi, and J. Priller, “Macrophage compartmentalization in the brain and cerebrospinal fluid system,” Sci. Immunol. 7(69), eabk0391 (2022).

70. M. Bear, B. Connors, and M. A. Paradiso, Neuroscience: Exploring the Brain, Lippincott Williams & Wilkins (2006).

71. R. M. Ransohoff and B. Engelhardt, “The anatomical and cellular basis of immune surveillance in the central nervous system,” Nat. Rev. Immunol. 12(9), 623–635 (2012).

72. M. L. Upton and R. O. Weller, “The morphology of cerebrospinal fluid drainage pathways in human arachnoid granulations,” J. Neurosurg. 63(6), 867–875 (1985).

73. A. Aspelund et al., “A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules,” J. Exp. Med. 212(7), 991–999 (2015).

74. Q. Ma et al., “Outflow of cerebrospinal fluid is predominantly through lymphatic vessels and is reduced in aged mice,” Nat. Commun. 8, 1434 (2017).

75. G. Ringstad and P. K. Eide, “Cerebrospinal fluid tracer efflux to parasagittal dura in humans,” Nat. Commun. 11, 354 (2020).

76. S. T. Proulx, “Cerebrospinal fluid outflow: a review of the historical and contemporary evidence for arachnoid villi, perineural routes, and dural lymphatics,” Cell Mol. Life Sci. 78(6), 2429–2457 (2021).

77. G. Oliver et al., “The lymphatic vasculature in the 21(st) century: novel functional roles in homeostasis and disease,” Cell 182(2), 270–296 (2020).

78. B. Engelhardt, “Molecular mechanisms involved in T cell migration across the blood–brain barrier,” J. Neural Transm. (Vienna) 113(4), 477–485 (2006).

79. M. Greter et al., “Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis,” Nat. Med. 11(3), 328–334 (2005).

80. R. Balabanov, T. Beaumont, and P. Dore-Duffy, “Role of central nervous system microvascular pericytes in activation of antigen primed splenic T-lymphocytes,” J. Neurosci. Res. 55(5), 578–587 (1999).

81. C. L. Maier and J. S. Pober, “Human placental pericytes poorly stimulate and actively regulate allogeneic CD4 T cell responses,” Arterioscler. Thromb. Vasc. Biol. 31(1), 183–189 (2011).

82. S. Nourshargh and R. Alon, “Leukocyte migration into inflamed tissues,” Immunity 41(5), 694–707 (2014).

83. H. Wolburg, K. Wolburg-Buchholz, and B. Engelhardt, “Diapedesis of mononuclear cells across cerebral venules during experimental autoimmune encephalomyelitis leaves tight junctions intact,” Acta Neuropathol. 109(2), 181–190 (2005).

84. M. Abadier et al., “Cell surface levels of endothelial ICAM-1 influence the transcellular or paracellular T-cell diapedesis across the blood–brain barrier,” Eur. J. Immunol. 45(4), 1043–1058 (2015).

85. C. Minten et al., “DARC shuttles inflammatory chemokines across the blood–brain barrier during autoimmune central nervous system inflammation,” Brain 137(5), 1454–1469 (2014).

86. M. von Wedel-Parlow et al., “Neutrophils cross the BBB primarily on transcellular pathways: an in vitro study,” Brain Res. 1367, 62–76 (2011).

87. M. Castro Dias et al., “Brain endothelial tricellular junctions as novel sites for T cell diapedesis across the blood–brain barrier,” J. Cell Sci. 134(8), jes253880 (2021).

88. T. M. Mathiesen et al., “The perivascular astroglial sheath provides a complete covering of the brain microvessels: an electron microscopic 3D reconstruction,” Glia 58(9), 1094–1103 (2010).

89. M. J. Hotz et al., “Red blood cells homeostatically bind mitochondrial DNA through TLR9 to maintain quiescence and to prevent lung injury,” Am. J. Respir. Crit. Care Med. 197(4), 470–480 (2018).
91. L. K. M. Lam et al., “DNA binding to TLR9 expressed by red blood cells promotes innate immune activation and anemia,” Sci. Transl. Med. 13(616), eabj1008 (2021).
92. R. J. Nibbs and G. J. Graham, “Immune regulation by atypical chemokine receptors,” Nat. Rev. Immunol. 13(11), 815–829 (2013).
93. M. A. Lopes Pinheiro et al., “Immune cell trafficking across the barriers of the central nervous system in multiple sclerosis and stroke,” Biochim. Biophys. Acta 1862(3), 461–471 (2016).
94. S. H. Baik et al., “Migration of neutrophils targeting amyloid plaques in Alzheimer’s disease mouse model,” Neurobiol. Aging 35(6), 1286–1292 (2014).
95. E. Zenaro et al., “Neutrophils promote Alzheimer’s disease-like pathology and cognitive decline via LFA-1 integrin,” Nat. Med. 21(8), 880–886 (2015).
96. R. K. Clark et al., “Reperfusion following focal stroke hastens inflammation and resolution of ischemic injured tissue,” Brain Res. Bull. 35(4), 387–392 (1994).
97. J. H. Garcia et al., “Influx of leukocytes and platelets in an evolving brain infarct (Wistar rat),” Am. J. Pathol. 144(1), 188–199 (1994).
98. J. Neumann et al., “Beware the intruder: real time observation of infiltrated neutrophils and neutrophil-Microglia interaction during stroke in vivo,” PLoS One 13(3), e0193970 (2018).
99. G. Enzmann et al., “The neurovascular unit as a selective barrier to polymorphonuclear granulocyte (PMN) infiltration into the brain after ischemic injury,” Acta Neuropathol. 125(3), 395–412 (2013).
100. M. Filippi et al., “Multiple sclerosis,” Nat. Rev. Dis. Primers 4(1), 43 (2018).
101. B. Rossi et al., “Vascular inflammation in central nervous system diseases: adhesion receptors controlling leukocyte-endothelial interactions,” J. Leukoc. Biol. 89(4), 539–556 (2011).
102. D. Proebstl et al., “Pericytes support neutrophil subendothelial cell crawling and breaching of venular walls in vivo,” J. Exp. Med. 209(6), 1219–1234 (2012).
103. K. Stark et al., “Capillary and arteriolar pericytes attract innate leukocytes exiting through venules and ‘instruct’ them with pattern-recognition and motility programs,” Nat. Immunol. 14(1), 41–51 (2013).
104. O. Torok et al., “Pericytes regulate vascular immune homeostasis in the CNS,” Proc. Natl. Acad. Sci. U. S. A. 118(10), e2016587118 (2021).
105. R. Daneman et al., “Pericytes are required for blood–brain barrier integrity during embryogenesis,” Nature 468(7323), 562–566 (2010).
106. S. Ogura et al., “Sustained inflammation after pericyte depletion induces irreversible blood-retina barrier breakdown,” JCI Insight 2(3), e90905 (2017).
107. D. Fu et al., “Survival or death: a dual role for autophagy in stress-induced pericyle loss in diabetic retinopathy,” Diabetologia 59(10), 2251–2261 (2016).
108. J. Rustenhoven et al., “Brain pericytes as mediators of neuroinflammation,” Trends Pharmacol. Sci. 38(3), 291–304 (2017).
109. L. Duan et al., “PDGFRbeta cells rapidly relay inflammatory signal from the circulatory system to neurons via chemokine CCL2,” Neuron 100(1), 183 (2018).
110. M. W. Carr et al., “Monocyte chemotactrant protein 1 acts as a T-lymphocyte chemoattractant,” Proc. Natl. Acad. Sci. U. S. A. 91(9), 3652–3656 (1994).
111. K. Matsushima et al., “Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line,” J. Exp. Med. 169(4), 1485–1490 (1989).
112. I. Novitzky-Basso and A. Rot, “Duffy antigen receptor for chemokines and its involvement in patterning and control of inflammatory chemokines,” Front. Immunol. 3, 266 (2012).
113. J. Hong et al., “Role of tumor pericytes in the recruitment of myeloid-derived suppressor cells,” J. Natl. Cancer Inst. 107(10), djv209 (2015).
114. R. Valdor et al., “Glioblastoma progression is assisted by induction of immunosuppressive function of pericytes through interaction with tumor cells,” Oncotarget 8(40), 68614–68626 (2017).
115. R. Valdor et al., “Glioblastoma ablates pericytes antitumor immune function through aberrant up-regulation of chaperone-mediated autophagy,” Proc. Natl. Acad. Sci. U. S. A. 116(41), 20655–20665 (2019).
116. W. Zhou et al., “Targeting glioma stem cell-derived pericytes disrupts the blood-tumor barrier and improves chemotherapeutic efficacy,” *Cell Stem Cell* 21(5), 591–603e4 (2017).

117. K. Huizer et al., “Periostin is expressed by pericytes and is crucial for angiogenesis in glioma,” *J. Neuropathol. Exp. Neurol.* 79(8), 863–872 (2020).

118. A. Sierra et al., “The “Big-Bang” for modern glial biology: translation and comments on Pio del Rio-Hortega 1919 series of papers on microglia,” *Glia* 64(11), 1801–1840 (2016).

119. K. Bisht et al., “Capillary-associated microglia regulate vascular structure and function through PANX1-P2RY12 coupling in mice,” *Nat. Commun.* 12, 5289 (2021).

120. E. Császár et al., “Microglia modulate blood flow, neurovascular coupling, and hypoperfusion via purinergic actions,” *J. Exp. Med.* 219(3), e20211071 (2022).

121. S. A. Mills et al., “Fractalkine-induced microglial vasoregulation occurs within the retina and is altered early in diabetic retinopathy,” *Proc. Natl. Acad. Sci. U S A* 118(51), e2112561118 (2021).

122. L. Park et al., “Brain perivascular macrophages initiate the neurovascular dysfunction of Alzheimer abeta peptides,” *Circ. Res.* 121(3), 258–269 (2017).

123. G. Faraco et al., “Dietary salt promotes neurovascular and cognitive dysfunction through a gut-initiated TH17 response,” *Nat. Neurosci.* 21(2), 240–249 (2018).

124. G. Faraco et al., “Dietary salt promotes cognitive impairment through tau phosphorylation,” *Nature* 574(7780), 686–690 (2019).

125. R. M. Pirzgalska et al., “Sympathetic neuron-associated macrophages contribute to obesity by importing and metabolizing norepinephrine,” *Nat. Med.* 23(11), 1309–1318 (2017).

126. A. Czopek et al., “A novel role for myeloid endothelin-B receptors in hypertension,” *Eur. Heart J.* 40(9), 768–784 (2019).

127. H. Y. Lim et al., “Hyaluronan receptor LYVE-1-expressing macrophages maintain arterial tone through hyaluronan-mediated regulation of smooth muscle cell collagen,” *Immunity* 49(2), 326–341e7 (2018).

128. J. C. Cruz Hernandez et al., “Neutrophil adhesion in brain capillaries reduces cortical blood flow and impairs memory function in Alzheimer’s disease mouse models,” *Nat. Neurosci.* 22(3), 413–420 (2019).

129. M. El Amki et al., “Neutrophils obstructing brain capillaries are a major cause of no-reflow in ischemic stroke,” *Cell Rep.* 33(2), 108260 (2020).

130. S. E. Erdener et al., “Dynamic capillary stalls in reperfused ischemic penumbra contribute to injury: a hyperacute role for neutrophils in persistent traffic jams,” *J. Cereb. Blood Flow Metab.* 41(2), 236–252 (2021).

131. L. Rolfs et al., “Neutrophil granulocytes promote flow stagnation due to dynamic capillary stalls following experimental stroke,” *Brain Behav. Immun.* 93, 322–330 (2021).

132. V. Jolivel et al., “Perivascular microglia promote blood vessel disintegration in the ischemic penumbra,” *Acta Neuropathol.* 129(2), 279–295 (2015).

133. E. M. F. Mehina et al., “Invasion of phagocytic Galectin 3 expressing macrophages in the diabetic brain disrupts vascular repair,” *Sci. Adv.* 7(34), eabg2712 (2021).

134. R. A. Adams et al., “The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease,” *J. Exp. Med.* 204(3), 571–582 (2007).

135. D. Davalos et al., “Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation,” *Nat. Commun.* 3, 1227 (2012).

136. M. Merlini et al., “Fibrinogen induces microglia-mediated spine elimination and cognitive impairment in an Alzheimer’s disease model,” *Neuron* 101(6), 1099–1108e6 (2019).

137. Y. Sasaki et al., “Selective expression of Gi/o-coupled ATP receptor P2Y12 in microglia in rat brain,” *Glia* 44(3), 242–250 (2003).

138. R. T. Dorsam and S. P. Kunapuli, “Central role of the P2Y12 receptor in platelet activation,” *J. Clin. Invest.* 113(3), 340–345 (2004).

139. K. Ohsawa et al., “P2Y12 receptor-mediated integrin-beta1 activation regulates microglial process extension induced by ATP,” *Glia* 58(7), 790–801 (2010).

140. S. E. Haynes et al., “The P2Y12 receptor regulates microglial activation by extracellular nucleotides,” *Nat. Neurosci.* 9(12), 1512–1519 (2006).
141. C. Madry et al., “Microglial ramification, surveillance, and interleukin-1beta release are regulated by the two-pore domain K(+) channel THIK-1,” *Neuron* 97(2), 299–312e6 (2018).
142. L. Dissing-Olesen et al., “Activation of neuronal NMDA receptors triggers transient ATP-mediated microglial process outgrowth,” *J. Neurosci.* 34(32), 10511–10527 (2014).
143. E. Mondo et al., “A developmental analysis of juxtavascular microglia dynamics and interactions with the vasculature,” *J. Neurosci.* 40(34), 6503–6521 (2020).
144. E. Joost et al., “Microglia contribute to the glia limitans around arteries, capillaries and veins under physiological conditions, in a model of neuroinflammation and in human brain tissue,” *Brain Struct. Funct.* 224(3), 1301–1314 (2019).
145. H. Lassmann et al., “Microglial cells are a component of the perivascular glia limitans,” *J. Neurosci. Res.* 28(2), 236–243 (1991).
146. P. Andre et al., “P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries,” *J. Clin. Invest.* 112(3), 398–406 (2003).
147. K. A. Taylor et al., “Amplification of human platelet activation by surface pannexin-1 channels,” *J. Thromb. Haemost.* 12(6), 987–998 (2014).
148. W. R. Silverman et al., “The pannexin 1 channel activates the inflammasome in neurons and astrocytes,” *J. Biol. Chem.* 284(27), 18143–18151 (2009).
149. J. C. Sanchez-Arias et al., “Pannexin 1 regulates network ensembles and dendritic spine development in cortical neurons,” *eNeuro* 6(3), ENEURO.0503-18.2019 (2019).
150. V. M. Kovalzon et al., “Sleep-wakefulness cycle and behavior in pannexin1 knockout mice,” *Behav. Brain Res.* 318, 24–27 (2017).
151. P. Bargiotas et al., “Pannexins in ischemia-induced neurodegeneration,” *Proc. Natl. Acad. Sci. U. S. A.* 108(51), 20772–20777 (2011).
152. N. L. Weilinger et al., “Metabotropic NMDA receptor signaling couples Src family kinases to pannexin-1 during excitotoxicity,” *Nat. Neurosci.* 19(3), 432–442 (2016).
153. M. Freitas-Andrade et al., “Pannexin1 knockout and blockade reduces ischemic stroke injury in female, but not in male mice,” *Oncotarget* 8(23), 36973–36983 (2017).
154. M. E. Good et al., “Endothelial cell Pannexin1 modulates severity of ischemic stroke by regulating cerebral inflammation and myogenic tone,” *JCI Insight* 3(6), e96272 (2018).
155. A. Mildner et al., “P2Y12 receptor is expressed on human microglia under physiological conditions throughout development and is sensitive to neuroinflammatory diseases,” *Glia* 65(2), 375–387 (2017).
156. M. G. Kluge et al., “Spatiotemporal analysis of impaired microglia process movement at sites of secondary neurodegeneration post-stroke,” *J. Cereb. Blood Flow Metab.* 39(12), 2456–2470 (2019).
157. T. Zrzavy et al., “Loss of ‘homeostatic’ microglia and patterns of their activation in active multiple sclerosis,” *Brain* 140(7), 1900–1913 (2017).
158. T. Tanaka et al., “Early-life stress induces the development of Alzheimer’s disease pathology via angiopathy,” *Exp. Neurol.* 337, 113552 (2021).
159. A. Krainik et al., “Regional impairment of cerebrovascular reactivity and BOLD signal in adults after stroke,” *Stroke* 36(6), 1146–1152 (2005).
160. R. Pineiro et al., “Altered hemodynamic responses in patients after subcortical stroke measured by functional MRI,” *Stroke* 33(1), 103–109 (2002).
161. B. Ongali et al., “Transgenic mice overexpressing APP and transforming growth factor-beta1 feature cognitive and vascular hallmarks of Alzheimer’s disease,” *Am. J. Pathol.* 177(6), 3071–3080 (2010).
162. D. Checchin et al., “Potential role of microglia in retinal blood vessel formation,” *Invest. Ophthalmol. Vis. Sci.* 47(8), 3595–3602 (2006).
163. T. Dudiki et al., “Microglia control vascular architecture via a TGFbeta1 dependent paracrine mechanism linked to tissue mechanics,” *Nat. Commun.* 11, 986 (2020).
164. A. Fantin et al., “Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction,” *Blood* 116(5), 829–840 (2010).
165. G. Faraco et al., “Perivascular macrophages mediate the neurovascular and cognitive dysfunction associated with hypertension,” *J. Clin. Invest.* 126(12), 4674–4689 (2016).
166. F. Gongora-Rivera et al., “In neurocysticercosis, CSF cytokines correlate with cerebral blood flow velocities,” *Neurology* 71(14), 1119–1122 (2008).

167. K. Fassbender et al., “Inflammatory cytokines in CSF in bacterial meningitis: association with altered blood flow velocities in basal cerebral arteries,” *J. Neurol. Neurosurg. Psychiatry* 61(1), 57–61 (1996).

168. K. Fassbender et al., “Inflammatory cytokines in subarachnoid haemorrhage: association with abnormal blood flow velocities in basal cerebral arteries,” *J. Neurol. Neurosurg. Psychiatry* 70(4), 534–537 (2001).

169. B. J. Balin et al., “Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey,” *J. Comp. Neurol.* 251(2), 260–280 (1986).

170. T. L. Roth et al., “Transcranial amelioration of inflammation and cell death after brain injury,” *Nature* 505(7482), 223–228 (2014).

171. M. L. Rennels et al., “Evidence for a ‘paravascular’ fluid circulation in the mammalian central nervous system, provided by the rapid distribution of tracer protein throughout the brain from the subarachnoid space,” *Brain Res.* 326(1), 47–63 (1985).

172. P. Sundd et al., “Biomechanics of leukocyte rolling,” *Biorheology* 48(1), 1–35 (2011).

173. S. Reitsma et al., “The endothelial glycocalyx: composition, functions, and visualization,” *Pflugers Arch.* 454(3), 345–359 (2007).

174. J.-H. Yoon et al., “Increased capillary stalling is associated with endothelial glycocalyx loss in subcortical vascular dementia,” *J. Cereb. Blood Flow Metab.*, 271678X221076568 (2022).

175. P. Cabrales et al., “Murine cerebral malaria is associated with a vasospasm-like microcirculatory dysfunction, and survival upon rescue treatment is markedly increased by nimo-dipine,” *Am. J. Pathol.* 176(3), 1306–1315 (2010).

176. S. Schroder, W. Palinski, and G. W. Schmid-Schönbein, “Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy,” *Am. J. Pathol.* 139(1), 81–100 (1991).

177. G. J. del Zoppo et al., “Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons,” *Stroke* 22(10), 1276–1283 (1991).

178. P. A. Reis et al., “Statins prevent cognitive impairment after sepsis by reverting neuroinflammation, and microcirculatory/endothelial dysfunction,” *Brain Behav. Immun.* 60, 293–303 (2017).

179. A. Pamplona et al., “Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria,” *Nat. Med.* 13(6), 703–710 (2007).

180. L. S. Ritter et al., “Leukocyte accumulation and hemodynamic changes in the cerebral microcirculation during early reperfusion after stroke,” *Stroke* 31(5), 1153–1161 (2000).

181. S. E. Akopov, N. A. Simonian, and G. S. Grigorian, “Dynamics of polymorphonuclear leukocyte accumulation in acute cerebral infarction and their correlation with brain tissue damage,” *Stroke* 27(10), 1739–1743 (1996).

182. P. Y. Wang, et al., “Leukocyte infiltration in acute hemispheric ischemic stroke,” *Stroke* 24(2), 236–240 (1993).

183. N. Korte et al., “The Ca2+-gated Cl− channel TMEM16A amplifies capillary pericyte contraction reducing cerebral blood flow after ischemia,” *J. Clin. Invest.* (2022).

184. C. Ducroux et al., “Thrombus neutrophil extracellular traps content impairs tPA-induced thrombolysis in acute ischemic stroke,” *Stroke* 49(3), 754–757 (2018).

185. S. Staessens et al., “Structural analysis of ischemic stroke thrombi: histological indications for therapy resistance,” *Haematologica* 105(2), 498–507 (2020).

186. D. Zhang et al., “Prostaglandin E2 released from activated microglia enhances astrocyte proliferation *in vitro*,” *Toxicol. Appl. Pharmacol.* 238(1), 64–70 (2009).

187. M. Shibata, C. W. Leftler, and D. W. Busija, “Recombinant human interleukin 1 alpha dilates pial arterioles and increases cerebrospinal fluid prostanoids in piglets,” *Am. J. Physiol.* 259(5 Pt 2), H1486–H1491 (1990).

188. K. M. Boje and P. K. Arora, “Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death,” *Brain Res.* 587(2), 250–256 (1992).
189. C. Kelley et al., “Vasoactive hormones and cAMP affect pericyte contraction and stress fibres in vitro,” J. Muscle Res. Cell Motil. 9(2), 184–194 (1988).

190. N. Markhotina, G. J. Liu, and D. K. Martin, “Contractility of retinal pericytes grown on silicone elastomer substrates is through a protein kinase A-mediated intracellular pathway in response to vasoactive peptides,” IET Nanobiotechnol. 1(3), 44–51 (2007).

191. U. Schonfelder et al., “In situ observation of living pericytes in rat retinal capillaries,” Microvasc. Res. 56(1), 22–29 (1998).

192. D. D. Murphy and R. C. Wagner, “Differential contractile response of cultured microvascular pericytes to vasoactive agents,” Microcirculation 1(2), 121–128 (1994).

193. U. Wagner and M. Wiederholt, “Membrane voltage and whole-cell currents in cultured pericytes of control rats and rats with retinal dystrophy,” Curr. Eye Res. 15(10), 1045–1053 (1996).

194. H. Helbig et al., “Membrane potentials in retinal capillary pericytes: excitability and effect of vasoactive substances,” Invest. Ophthalmol. Vis. Sci. 33(7), 2105–2112 (1992).

195. R. F. Gaertner et al., “Reduced brain tissue perfusion in TGF-beta 1 transgenic mice showing Alzheimer’s disease-like cerebrovascular abnormalities,” Neurobiol. Dis. 19(1-2), 38–46 (2005).

196. T. Kato et al., “Excessive production of transforming growth factor beta1 causes mural cell depletion from cerebral small vessels,” Front. Aging Neurosci. 12, 151 (2020).

197. M. F. Iulita et al., “CD4(+) regulatory T lymphocytes prevent impaired cerebral blood flow in angiotensin II-induced hypertension,” J. Am. Heart Assoc. 8(1), e009372 (2019).

198. S. A. Zambach et al., “Precapillary sphincters and pericytes at first-order capillaries as key regulators for brain capillary perfusion,” Proc. Natl. Acad. Sci. U. S. A. 118(26), e2023749118 (2021).

199. C. Madry et al., “Effects of the ecto-ATPase apyrase on microglial ramification and surveillance reflect cell depolarization, not ATP depletion,” Proc. Natl. Acad. Sci. U. S. A. 115(7), E1608–E1617 (2018).

200. T. A. Longden et al., “Local IP3 receptor-mediated Ca(2+) signals compound to direct blood flow in brain capillaries,” Sci. Adv. 7(30), eabt0101 (2021).

201. A. K. Clark et al., “Selective activation of microglia facilitates synaptic strength,” J. Neurosci. 35(11), 4552–4570 (2015).

202. C. Cao et al., “Pyrogenic cytokines injected into the rat cerebral ventricle induce cyclooxygenase-2 in brain endothelial cells and also upregulate their receptors,” Eur. J. Neurosci. 13(9), 1781–1790 (2001).

203. X. Liu et al., “Interleukin 1 type 1 receptor restore: a genetic mouse model for studying interleukin 1 receptor-mediated effects in specific cell types,” J. Neurosci. 35(7), 2860–2870 (2015).

204. M. Monroy et al., “Role of nitric oxide in the cerebrovascular and thermoregulatory response to interleukin-1 beta,” Am. J. Physiol. Heart Circ. Physiol. 280(4), H1448–H1453 (2001).

205. M. Shibata et al., “Nitric oxide regulates NMDA-induced dopamine release in rat striatum,” Neuropoietics 7(2), 605–608 (1996).

206. M. Yemisci et al., “Pericyte contraction induced by oxidative-nitrative stress impairs capillary reflow despite successful opening of an occluded cerebral artery,” Nat. Med. 15(9), 1031–1037 (2009).

207. V. D. Bianca et al., “Beta-amyloid activates the O–O forming NADPH oxidase in microglia, monocytes, and neutrophils. A possible inflammatory mechanism of neuronal damage in Alzheimer’s disease,” J. Biol. Chem. 274(22), 15493–15499 (1999).

208. O. Mossad et al., “Gut microbiota drives age-related oxidative stress and mitochondrial damage in microglia via the metabolite N(6)-carboxymethyllysine,” Nat. Neurosci. 25(3), 295–305 (2022).

209. E. P. Wei, H. A. Kontos, and J. S. Beckman, “Mechanisms of cerebral vasodilation by superoxide, hydrogen peroxide, and peroxynitrite,” Am. J. Physiol. 271(3 Pt 2), H1262–H1266 (1996).
210. E. Farkas et al., “Tumor necrosis factor-alpha increases cerebral blood flow and ultrastructural capillary damage through the release of nitric oxide in the rat brain,” Microvasc. Res. 72(3), 113−119 (2006).
211. C. O. Maher et al., “Interleukin-1beta and adverse effects on cerebral blood flow during long-term global hypoperfusion,” J. Neurosurg. 99(5), 907−912 (2003).
212. M. Kamouchi et al., “Hydrogen peroxide-induced Ca2+ responses in CNS pericytes,” Neurosci. Lett. 416(1), 12−16 (2007).
213. H. Girouard et al., “Cerebrovascular nitrosative stress mediates neurovascular and endothelial dysfunction induced by angiotensin II,” Arterioscler. Thromb. Vasc. Biol. 27(2), 303−309 (2007).
214. K. Kazama et al., “Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals,” Circ. Res. 95(10), 1019−1026 (2004).
215. M. J. Hung et al., “Interleukin-6 inhibits endothelial nitric oxide synthase activation and increases endothelial nitric oxide synthase binding to stabilized caveolin-1 in human vascular endothelial cells,” J. Hypertens. 28(5), 940−951 (2010).
216. J. M. Stouthard et al., “Interleukin-6 stimulates coagulation, not fibrinolysis, in humans,” Thromb. Haemost. 76(5), 738−742 (1996).
217. C. Gluck et al., “Distinct signatures of calcium activity in brain mural cells,” Elife 10, e70591 (2021).
218. T. A. Longden and M. T. Nelson, “Vascular inward rectifier K+ channels as external K+ sensors in the control of cerebral blood flow,” Microcirculation 22(3), 183−196 (2015).
219. J. A. Filosa et al., “Local potassium signaling couples neuronal activity to vasodilation in the brain,” Nat. Neurosci. 9(11), 1397−1403 (2006).
220. Y. Fukata, M. Amano, and K. Kaibuchi, “Rho-rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells,” Trends Pharmacol. Sci. 22(1), 32−39 (2001).
221. Q. Li and D. G. Puro, “Adenosine activates ATP-sensitive K(+) currents in pericytes of rat retinal microvessels: role of A1 and A2a receptors,” Brain Res. 907(1-2), 93−99 (2001).
222. U. Dimagl et al., “Coupling of cerebral blood flow to neuronal activation: role of adenosine and nitric oxide,” Am. J. Physiol. 267(1 Pt 2), H296−H301 (1994).
223. S. Horlyck et al., “ATP induces contraction of cultured brain capillary pericytes via activation of P2Y-type purinergic receptors,” Am. J. Physiol. Heart Circ. Physiol. 320(2), H699−H712 (2021).
224. B. S. Khakh et al., “International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits,” Pharmacol. Rev. 53(1), 107−118 (2001).
225. H. Kawamura et al., “ATP: a vasoactive signal in the pericyte-containing microvasculature of the rat retina,” J. Physiol. 551(3), 787−799 (2003).
226. C. Cai et al., “Impaired dynamics of brain precapillary sphincters and pericytes at first order capillaries explains reduced neurovascular functions in aging,” bioRxiv (2021).
227. T. Sugiyama et al., “Regulation of P2X7-induced pore formation and cell death in pericyte-containing retinal microvessels,” Am. J. Physiol. Cell Physiol. 288(3), C568–C576 (2005).
228. A. D. Umprierre et al., “Microglial calcium signaling is attuned to neuronal activity in awake mice,” Elife 9, e56502 (2020).
229. H. B. Choi et al., “Differential activation of subtype purinergic receptors modulates Ca(2+) mobilization and COX-2 in human microglia,” Glia 43(2), 95−103 (2005).
230. C. Hundhausen et al., “Regulated shedding of transmembrane chemokines by the disintegrin and metalloproteinase 10 facilitates detachment of adherent leukocytes,” J. Immunol. 178(12), 8064−8072 (2007).
231. S. A. Jones et al., “Shedding of the soluble IL-6 receptor is triggered by Ca2+ mobilization, while basal release is predominantly the product of differential mRNA splicing in THP-1 cells,” Eur. J. Immunol. 28(11), 3514−3522 (1998).
232. G. S. Lee et al., “The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP,” Nature 492(7427), 123−127 (2012).
233. S. M. Le Gall et al., “ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, L-selectin, and tumor necrosis factor alpha,” *Mol. Biol. Cell* 20(6), 1785–1794 (2009).

234. C. Madry and D. Attwell, “Receptors, ion channels, and signaling mechanisms underlying microglial dynamics,” *J. Biol. Chem.* 290(20), 12443–12450 (2015).

235. J. T. Rogers et al., “CX3CR1 deficiency leads to impairment of hippocampal cognitive function and synaptic plasticity,” *J. Neurosci.* 31(45), 16241–16250 (2011).

236. J. D. Sokolowski et al., “Fractalkine is a ‘find-me’ signal released by neurons undergoing ethanol-induced apoptosis,” *Front. Cell Neurosci.* 8, 360 (2014).

237. A. Denes et al., “Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse,” *J. Cereb. Blood Flow Metab.* 28(10), 1707–1721 (2008).

238. J. Wang et al., “Ischemia-induced neuronal cell death is mediated by chemokine receptor CX3CR1,” *Sci. Rep.* 8(1), 556 (2018).

239. D. B. Re and S. Przedborski, “Fractalkine: moving from chemotaxis to neuroprotection,” *Nat. Neurosci.* 9(7), 859–861 (2006).

240. R. B. Guo et al., “Iptakalim improves cerebral microcirculation in mice after ischemic stroke by inhibiting pericyte contraction,” *Acta Pharmacol. Sin.*, 1–11 (2021).

241. D. Weisenburger-Lile et al., “Harmful neutrophil subsets in patients with ischemic stroke: association with disease severity,” *Neurol. Neuroimmunol. Neuroinflamm.* 6(4), e571 (2019).

242. M. D’Haeseleer et al., “Cerebral hypoperfusion in multiple sclerosis is reversible and mediated by endothelin-1,” *Proc. Natl. Acad. Sci. U. S. A.* 110(14), 5654–5658 (2013).

243. S. Shahrampour et al., “N-acetyl cysteine administration affects cerebral blood flow as measured by arterial spin labeling MRI in patients with multiple sclerosis,” *Heliyon* 7(7), e07615 (2021).

244. A. Liesz et al., “Intracerebral interleukin-10 injection modulates post-ischemic neuroinflammation: an experimental microarray study,” *Neurosci. Lett.* 579, 18–23 (2014).

245. J. Milovanovic et al., “Interleukin-17 in chronic inflammatory neurological diseases,” *Front. Immunol.* 11, 947 (2020).

246. B. Hotter et al., “IL-6 plasma levels correlate with cerebral perfusion deficits and infarct sizes in stroke patients without associated infections,” *Front. Neurol.* 10, 83 (2019).

247. K. N. Warren et al., “Elevated markers of inflammation are associated with longitudinal changes in brain function in older adults,” *J. Gerontol. A Biol. Sci. Med. Sci.* 73(6), 770–778 (2018).

248. Y. Qin et al., “Long-term microstructure and cerebral blood flow changes in patients recovered from COVID-19 without neurological manifestations,” *J. Clin. Invest.* 131(8), e147329 (2021).

249. A. Varatharaj et al., “Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study,” *Lancet Psychiatry* 7(10), 875–882 (2020).

250. M. Taquet et al., “6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records,” *Lancet Psychiatr.* 8(5), 416–427 (2021).

251. T. Sharshar et al., “The neuropathology of septic shock,” *Brain Pathol.* 14(1), 21–33 (2004).

252. A. Polito et al., “Pattern of brain injury in the acute setting of human septic shock,” *Crit. Care* 17(5), R204 (2013).

253. F. S. Taccone et al., “Cerebral microcirculation is impaired during sepsis: an experimental study,” *Crit. Care* 14(4), R140 (2010).

254. F. S. Taccone et al., “Sepsis is associated with altered cerebral microcirculation and tissue hypoxia in experimental peritonitis,” *Crit. Care Med.* 42(2), e114–e122 (2014).

255. J. G. Wilson et al., “Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis,” *JCI Insight* 5(17), e140289 (2020).

256. J. Liu et al., “Lymphopenia predicted illness severity and recovery in patients with COVID-19: a single-center, retrospective study,” *PLoS One* 15(11), e0241659 (2020).
257. L. Tan et al., “Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study,” *Signal Transduct. Target Ther.* 5(1), 33 (2020).

258. L. Chang et al., “Perfusion MRI detects rCBF abnormalities in early stages of HIV-cognitive motor complex,” *Neurology* 54(2), 389–389 (2000).

259. C. Li et al., “Longitudinal diffusion tensor imaging and perfusion MRI investigation in a macaque model of neuro-AIDS: a preliminary study,” *Neuroimage* 58(1), 286–292 (2011).

260. L. He et al., “SARS-CoV-2 binding to ACE2 triggers pericyte-mediated angiotensin-evoked cerebral capillary constriction,” bioRxiv (2021).

261. J. Wenzel et al., “The SARS-CoV-2 main protease M(pro) causes microvascular brain pathology by cleaving NEMO in brain endothelial cells,” *Nat. Neurosci.* 24(11): 1522–1533 (2021).

262. L. He et al., “Pericyte-specific vascular expression of SARS-CoV-2 receptor ACE2—implications for microvascular inflammation and hypercoagulopathy in COVID-19 patients,” bioRxiv (2020).

263. D. Asby et al., “Systemic infection exacerbates cerebrovascular dysfunction in Alzheimer’s disease,” *Brain* 144(6), 1869–1883 (2011).

264. N. Korte, R. Nortley, and D. Attwell, “Cerebral blood flow decrease as an early pathological mechanism in Alzheimer’s disease,” *Acta Neuropathol.* 140(6), 793–810 (2020).

265. N. J. Abbott et al., “Structure and function of the blood–brain barrier,” *Neurobiol. Dis.* 37(1), 13–25 (2010).

266. R. N. Munji et al., “Profiling the mouse brain endothelial transcriptome in health and disease models reveals a core blood–brain barrier dysfunction module,” *Nat. Neurosci.* 22(11), 1892–1902 (2019).

267. S. Tietz and B. Engelhardt, “Brain barriers: crosstalk between complex tight junctions and adherens junctions,” *J. Cell Biol.* 209(4), 493–506 (2015).

268. B. Wojciak-Stothard et al., “Regulation of TNF-alpha-induced reorganization of the actin cytoskeleton and cell-cell junctions by Rho, Rac, and Cdc42 in human endothelial cells,” *J. Cell Physiol.* 176(1), 150–165 (1998).

269. G. Schreibelt et al., “Reactive oxygen species alter brain endothelial tight junction dynamics via RhoA, PI3 kinase, and PKB signaling,” *FASEB J.* 21(13), 3666–3676 (2007).

270. C. E. Walder et al., “Ischemic stroke injury is reduced in mice lacking a functional NADPH oxidase,” *Stroke* 28(11), 2252–2258 (1997).

271. J. M. Gidday et al., “Leukocyte-derived matrix metalloproteinase-9 mediates blood–brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia,” *Am. J. Physiol. Heart Circ. Physiol.* 289(2), H558–H568 (2005).

272. A. M. Stowe et al., “Neutrophil elastase and neurovascular injury following focal stroke and reperfusion,” *Neurobiol. Dis.* 35(1), 82–90 (2009).

273. R. G. Rempe, A. M. S. Hartz, and B. Bauer, “Matrix metalloproteinases in the brain and blood–brain barrier: versatile breakers and makers,” *J. Cereb. Blood Flow Metab.* 36(9), 1481–1507 (2016).

274. E. Candelario-Jalil, Y. Yang, and G. A. Rosenberg, “Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia,” *Neuroscience* 158(3), 983–994 (2009).

275. A. Rosell et al., “MMP-9-positive neutrophil infiltration is associated to blood–brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke,” *Stroke* 39(4), 1121–1126 (2008).

276. H. X. Nguyen, T. J. O’Barr, and A. J. Anderson, “Polymorphonuclear leukocytes promote neurotoxicity through release of matrix metalloproteinases, reactive oxygen species, and TNF-alpha,” *J. Neurochem.* 102(3), 900–912 (2007).

277. J. A. Siegenthaler, F. Sohet, and R. Daneman, “Sealing off the CNS: cellular and molecular regulation of blood–brain barrierogenesis,” *Curr. Opin. Neurobiol.* 23(6), 1057–1064 (2013).

278. B. W. Chow et al., “Caveolae in CNS arterioles mediate neurovascular coupling,” *Nature* 579(797), 106–110 (2020).

279. B. J. Andreone et al., “Blood–brain barrier permeability is regulated by lipid transport-dependent suppression of caveolae-mediated transcytosis,” *Neuron* 94(3), 581–594e5 (2017).
Barkaway, Attwell, and Korte: Immune–vascular mural cell interactions: consequences for immune cell...
Anna Barkaway studied biochemistry at the University of Reading, and completed her PhD in the Laboratory of Professor Sussan Nourshargh at Queen Mary, University of London, where she studied the impact of aging on neutrophil–vessel wall interactions. For her post-doctoral work, in Professor David Attwell’s Laboratory, she is investigating the impact of immune–vascular cell interactions on CBF in health and disease.

David Attwell studied physics at Oxford, before carrying out a PhD in neurophysiology. After a post-doctoral fellowship in Berkeley, he moved to University College London. He works on interactions between neurons, glial cells, and the vasculature, focussing on the role of contractile pericytes as regulators of capillary blood flow.

Nils Korte studied physiology in Glasgow and Melbourne, and did his PhD at University College London on the regulation of CBF in health, stroke, and AD. His post-doctoral work involves studying on vascular–immune interactions in the brain and brain-bordering tissues.